Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› New Jersey
Clinical trial register · United States · industry-sponsored

Clinical Trials in New Jersey, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9125 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 08 Oct 2026, 03:16 UTC
9125
Studies in scope
industry-sponsored, all four open statuses
4951
Recruiting now
open to new participants
2192
Lead sponsors
across recruiting studies
Top states
California 81 Florida 71 Illinois 50 Georgia 49 Arizona 37
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Trials with a site in New Jersey

22 of 9125 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Risk of Progressive Multifocal Leukoencephalopathy Among Patients With Multiple Sclerosis Exposed to Zeposia
NCT07732907Multiple Sclerosis, Progressive Multifocal Leukoencephalopathy
Bristol-Myers Squibb
Observational
15
New Jersey
2026-06-04
Recruiting
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
NCT07291076Hepatocellular Carcinoma (HCC)
Bristol-Myers Squibb
Phase 1/2
198
California, Illinois, Michigan, New Jersey, New York, Oregon, Tennessee, Washington
2026-03-16
Recruiting
A Study to Evaluate the Effect of KarXT on Urological Safety
NCT07221877Schizophrenia
DrugKarXT
Bristol-Myers Squibb
Phase 4
60
Arkansas, California, Florida, Illinois, Nevada, New Jersey, Pennsylvania, Texas
2026-01-20
Recruiting
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
NCT07175285Systemic Lupus Erythematosus (SLE)
Bristol-Myers Squibb
Observational
223
California, Florida, Georgia, Illinois, Maryland, Michigan, Montana, New Jersey
2025-10-08
Recruiting
Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)
NCT07101094Schizophrenia
Bristol-Myers Squibb
Observational
300
California, Florida, Illinois, Maryland, Massachusetts, Nebraska, New Jersey, New York
2025-09-22
Recruiting
A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT
NCT07061288Schizophrenia
DrugKarXT
Bristol-Myers Squibb
Phase 1
131
California, Florida, Georgia, Illinois, New Jersey, Texas
2025-09-03
Recruiting
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
NCT06408259Multiple Sclerosis, Relapsing-Remitting
Bristol-Myers Squibb
Phase 3
194
California, Florida, Illinois, Kentucky, New Jersey, Ohio, Oregon, Texas
2025-04-08
Recruiting
A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
NCT06764771Advanced Malignant Tumors
Bristol-Myers Squibb
Phase 1
437
New Jersey, Pennsylvania, Tennessee, Texas
2025-03-25
Recruiting
A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
NCT06697197Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2
413
California, Colorado, New Jersey, New York, North Carolina, Washington
2025-02-17
Active, closed
A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
NCT06730750Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2
360
California, Michigan, New Jersey, Pennsylvania
2025-02-12
Recruiting
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
NCT06618287Lung Cancer, Breast Cancer
Bristol-Myers Squibb
Phase 1/2
416
Alabama, Florida, Iowa, Missouri, New Jersey, Ohio, Oregon, Pennsylvania
2025-02-04
Recruiting
A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
NCT06476808High-grade Serous Ovarian Carcinoma (HGSOC), Uterine Serous Carcinoma (USC), Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb
Phase 1
240
California, New Jersey, Ohio, Texas
2024-09-06
Active, closed
A Study on the Safety of Deucravacitinib Exposure in Pregnant Women and Their Offspring
NCT06710470Psoriasis
Bristol-Myers Squibb
Observational
833
New Jersey
2024-08-02
Active, closed
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
NCT06122779Heart Failure
Bristol-Myers Squibb
Phase 2
227
Alabama, Colorado, Florida, Illinois, Indiana, Missouri, New Jersey, New York
2023-11-07
Active, closed
A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants
NCT06045689Myelodysplastic Syndromes
Bristol-Myers Squibb
Phase 3
106
California, Connecticut, Florida, Kansas, Kentucky, Michigan, Missouri, New Jersey
2023-10-05
Active, closed
A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors
NCT05888831Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2
100
California, Connecticut, New Jersey, New York
2023-06-06
Recruiting
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
NCT05372354Multiple Myeloma
Bristol-Myers Squibb
Phase 1/2
260
Alabama, Maryland, Massachusetts, New Jersey, New York
2022-10-18
Recruiting
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
NCT05245500Mesothelioma, Non Small Cell Lung Cancer, Malignant Peripheral Nerve Sheath Tumors, Solid Tumor
Bristol-Myers Squibb
Phase 1
336
Arizona, Colorado, Florida, Illinois, Massachusetts, Michigan, Minnesota, New Jersey
2022-06-09
Active, closed
A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate
NCT04909801Rheumatoid Arthritis
Bristol-Myers Squibb
Phase 3
338
California, Colorado, Maryland, Minnesota, New Jersey, New York, North Carolina, Oregon
2021-09-15
Recruiting
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
NCT04895709Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer
Bristol-Myers Squibb
Phase 1/2
1,109
California, Iowa, New Jersey, New York, Oregon, Tennessee, Texas
2021-05-27
Active, closed
A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)
NCT04817007Myelofibrosis
Bristol-Myers Squibb
Phase 1/2
216
California, Florida, Louisiana, Massachusetts, Michigan, New Jersey, North Carolina, Pennsylvania
2021-03-22
Active, closed
An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis
NCT01357668Juvenile Idiopathic Arthritis
Bristol-Myers Squibb
Observational
800
Arkansas, New Jersey, Ohio
2013-01-30
Rows per page Showing 1–22 of 22
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 8 October 2026. https://priyalifescience.com/clinical-trials-usa/state/new-jersey

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,125 studies in total at the last sync on 08 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 22 of those studies with a site in New Jersey that also match the filters currently applied.

How many clinical trials are recruiting in New Jersey?

14 of the 22 studies on this page are recruiting new participants as of the 08 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 8 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (New Jersey), 22 studies
PhaseStudiesRecruitingShare
Phase 1/28536.4%
Observational5322.7%
Phase 14418.2%
Phase 33113.6%
Phase 2104.5%
Phase 4114.5%

Most active sponsors

Lead sponsors with the most studies (New Jersey)
Lead sponsorStudiesRecruiting
Bristol-Myers Squibb2214
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.